<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="is required for IAV replication, and adamantane-based M2 inhibitors including" exact="amantadine" post="(1) and rimantadine (2; Fig. 1 ) were historically"/>
 <result pre="IAV replication, and adamantane-based M2 inhibitors including amantadine (1) and" exact="rimantadine" post="(2; Fig. 1 ) were historically used as influenza"/>
 <result pre="of adamantane-resistant M2. Fig. 1 The two FDA approved adamantanes" exact="amantadine" post="(1) and rimantadine (2). Recent advances in molecular and"/>
 <result pre="Fig. 1 The two FDA approved adamantanes amantadine (1) and" exact="rimantadine" post="(2). Recent advances in molecular and structural biology, electrophysiology,"/>
 <result pre="WT M2 is effectively antagonized by two FDA-approved adamantane-class drugs," exact="amantadine" post="(1) and rimantadine (2) (Fig. 1), in addition to"/>
 <result pre="effectively antagonized by two FDA-approved adamantane-class drugs, amantadine (1) and" exact="rimantadine" post="(2) (Fig. 1), in addition to numerous other adamantane"/>
 <result pre="Reference Assay IC50/EC50 Virus Strain MDCK cell toxicity (CC50) 1" exact="Amantadine" post="Image 1 TEVC WT: 16 μMV27A: &amp;gt; 500 μMS31N:"/>
 <result pre="al. (2013a) PRA WT: 0.3 μMS31N: 22 μM A/WSN/33 2" exact="Rimantadine" post="Image 2 TEVC WT: 11 μMS31N: &amp;gt; 2 mM"/>
 <result pre="μMV27A:31.3 μM A/Udorn/72 NR Wang et al. (2011b) 23 Hexamethylene" exact="amiloride" post="Image 23 SEVC WT: 1.3 μMS31N: 10% inhibition at"/>
 <result pre="B/Lee/40. CPE S31N: 0.7 μM A/PR/8/34 S31N: 1.9 μM A/CA/07/09" exact="Amantadine" post="first obtained FDA approval in 1966 under the brand"/>
 <result pre="2000). Additionally, the molecular mechanism describing a direct link between" exact="amantadine" post="and virus inhibition was not described until more than"/>
 <result pre="under the brand name Flumadine, is a methylated derivative of" exact="amantadine" post="which was licensed by FDA for the same indications"/>
 <result pre="5 ). In the first reported crystallographic structure of M2-bound" exact="amantadine" post="at pH 5.3 (PDB: 3C9J), Stouffer et al. (2008)"/>
 <result pre="pH 5.3 (PDB: 3C9J), Stouffer et al. (2008) suggested that" exact="amantadine" post="binds in a pocket located inside the intraluminal cavity"/>
 <result pre="by decreasing the pore size and occluding stable access of" exact="amantadine" post="to the pore (Stouffer et al., 2008). Fig. 5"/>
 <result pre="2009; Schnell and Chou, 2008, Fig. 5B). In these studies," exact="rimantadine" post="was found to bind to Asp44 on the C-terminal,"/>
 <result pre="drug binding pocket as a result of Ser31Asn mutation rendered" exact="rimantadine" post="incapable of effectively binding to the allosteric site (Pielak"/>
 <result pre="to alanine, Jing and coworkers continued to observe inhibition by" exact="amantadine" post="in both electrophysiological and antiviral plaque assays, suggesting that"/>
 <result pre="substitution with the M2 transmembrane domain from influenza A restored" exact="amantadine" post="sensitivity (Jing et al., 2008). Using solid-state NMR, Cady"/>
 <result pre="channel pore was the preferred binding site (PDB: 2KQT), where" exact="amantadine" post="preferentially localized to a hydrophobic cage formed by Ala30,"/>
 <result pre="adamantane cage were also observed, and the ammonium group of" exact="amantadine" post="showed hydrogen bonding to water molecules and pore-facing residues"/>
 <result pre="with the allosteric binding site were observed only at high" exact="amantadine" post="concentrations and were thus less probable as the primary"/>
 <result pre="Asp44Asn, Asp44Phe, Asp44Gly, and Asp44Thr) did not affect inhibition by" exact="amantadine" post="(Balannik et al., 2010). Notably, in further testing their"/>
 <result pre="testing their initial hypothesis of an allosteric binding site of" exact="amantadine" post="to M2, Pielak et al. (2011) next generated an"/>
 <result pre="proposed allosteric binding mechanism, using solution NMR, they described the" exact="rimantadine" post="binding pocket to be preserved within the pore of"/>
 <result pre="allosteric binding site, although the latter did remain sensitive to" exact="amantadine" post="(Rosenberg and Casarotto, 2010). Another computational study using small"/>
 <result pre="al., 2018, 2019). Taken together, these follow-up studies support that" exact="amantadine" post="inhibits IAV M2 by plugging the pore (Fig. 5A)."/>
 <result pre="the binding affinities of the R and S enantiomers of" exact="rimantadine" post="to M2 have also been questioned. Surprisingly, by comparing"/>
 <result pre="amantadine, M2 sequences containing Ser31Asn can still be inhibited by" exact="amantadine" post="in vitro, albeit with approximately 200-fold higher concentrations in"/>
 <result pre="changes between the observed interactions of the Ser31Asn channel and" exact="amantadine" post="when compared to WT M2 (Gleed et al., 2015)."/>
 <result pre="(A) X-ray crystal structure of M2-WT (22–46) in complex with" exact="amantadine" post="(1) (PDB: 6BKK; Thomaston et al., 2018). (B) Solution"/>
 <result pre="(Leu26Phe, Val27Ala, or Ser31Asn) with efficacies comparable or better than" exact="amantadine" post="against WT M2. While several other compounds are reported"/>
 <result pre="at low or sub-micromolar concentrations, which approximate the activities of" exact="amantadine" post="and rimantadine in these assays with wild-type M2. Clearly,"/>
 <result pre="or sub-micromolar concentrations, which approximate the activities of amantadine and" exact="rimantadine" post="in these assays with wild-type M2. Clearly, the efficacy"/>
 <result pre="that installation of aromatic groups to the amine group of" exact="amantadine" post="might also improve inhibitory activity against Ser31Asn M2 while"/>
 <result pre="design hypothesis lead to the synthesis and discovery of benzyl-substituted" exact="amantadine" post="derivatives, among which a benzdiol (7) was reported as"/>
 <result pre="Ser31Asn, respectively, as measured by TEVC. Compound 8 additionally inhibited" exact="amantadine" post="sensitive and resistant viruses with EC50 values of 4.6"/>
 <result pre="helix. Interestingly, Leu46Pro did not significantly change proton conductance or" exact="amantadine" post="sensitivity on its own in WT M2. However, in"/>
 <result pre="2019). Taken together, these results suggest that when compared to" exact="amantadine" post="and WT M2, the genetic barrier for drug resistance"/>
 <result pre="2011b). Another notably explored chemical class is exemplified by hexamethylene" exact="amiloride" post="(HMA, 23), an amiloride-based compound which is reported to"/>
 <result pre="single electrode voltage clamp (SEVC) experiments, which was comparable to" exact="amantadine" post="in these studies (IC50 0.2 μM vs 0.6 μM),"/>
 <result pre="of M2 inhibitors. As shown by Balgi and Roberge (2009)," exact="amantadine" post="restored the growth of yeast expressing WT M2 from"/>
 <result pre="has historically been an effective antiviral target for drugs like" exact="amantadine" post="and rimantadine. However, mutations in M2, particularly lining the"/>
 <result pre="bilayers from magic-angle-spinning solid-state NMR: the role of Ser31 in" exact="amantadine" post="bindingJ. Mol. Biol.38520091127114110.1016/j.jmb.2008.11.02219061899 CadyS.D.Schmidt-RohrK.WangJ.SotoC.S.DegradoW.F.HongM.Structure of the amantadine binding site"/>
 <result pre="of Ser31 in amantadine bindingJ. Mol. Biol.38520091127114110.1016/j.jmb.2008.11.02219061899 CadyS.D.Schmidt-RohrK.WangJ.SotoC.S.DegradoW.F.HongM.Structure of the" exact="amantadine" post="binding site of influenza M2 proton channels in lipid"/>
 <result pre="in mouse erythroleukaemia cellsJ. Physiol.494Pt 219963293368841994 ChuangG.Y.KozakovD.BrenkeR.BeglovD.GuarnieriF.VajdaS.Binding hot spots and" exact="amantadine" post="orientation in the influenza A virus M2 proton channelBiophys."/>
 <result pre="into antiviral drug targetsNat. Struct. Mol. Biol.17201053053810.1038/nsmb.177920383144 DaviesW.L.GrunertR.R.HaffR.F.McGahenJ.W.NeumayerE.M.PaulshockM.WattsJ.C.WoodT.R.HermannE.C.HoffmannC.E.Antiviral activity of" exact="1-adamantanamine" post="(amantadine)Science (80)144196486286310.1126/science.144.3620.862 DeydeV.M.XuX.BrightR.A.ShawM.SmithC.B.ZhangY.ShuY.GubarevaL.V.CoxN.J.KlimovA.I.Surveillance of resistance to adamantanes among influenza"/>
 <result pre="and drug-resistant mutant of the influenza A virus10.1016/j.ejmech.2015.12.0132016 DrakopoulosA.TzitzoglakiC.MaC.FreudenbergerK.HoffmannA.HuY.GauglitzG.SchmidtkeM.WangJ.KolocourisA.Affinity of" exact="rimantadine" post="enantiomers against influenza A/M2 protein revisitedACS Med. Chem. Lett.8201714515010.1021/acsmedchemlett.6b0031128217261"/>
 <result pre="viruses from different species: mechanisms for emergence and spread of" exact="amantadine" post="resistanceAntimicrob. Agents Chemother.5320094457446310.1128/AAC.00650-0919651904 GanS.-W.TanE.LinX.YuD.WangJ.TanG.M.-Y.VararattanavechA.YeoC.Y.SoonC.H.SoongT.W.PervushinK.TorresJ.The small hydrophobic protein of the"/>
 <result pre="copper complexes as influenza A M2 inhibitorsAntivir. Res.147201710010610.1016/j.antiviral.2017.10.00929032206 GrambasS.BennettM.S.HayA.J.Influence of" exact="amantadine" post="resistance mutations on the pH regulatory function of the"/>
 <result pre="2 function VACCINES ANDjvi.asm.org 1 J. Virol.9220181441145910.1128/JVI.01441-18 JingX.MaC.OhigashiY.OliveiraF.A.JardetzkyT.S.PintoL.H.LambR.A.Functional studies indicate" exact="amantadine" post="binds to the pore of the influenza A virus"/>
 <result pre="oocytesPLoS One132018e019922710.1371/journal.pone.0199227 KeyserL.A.KarlM.NafzigerA.N.BertinoJ.S.Comparison of central nervous system Adverse effects of" exact="amantadine" post="and rimantadine used as sequential prophylaxis of influenza A"/>
 <result pre="KeyserL.A.KarlM.NafzigerA.N.BertinoJ.S.Comparison of central nervous system Adverse effects of amantadine and" exact="rimantadine" post="used as sequential prophylaxis of influenza A in elderly"/>
 <result pre="influenza A M2 channelBiochem. Biophys. Res. Commun.4012010586310.1016/j.bbrc.2010.09.00820833142 PielakR.M.OxenoidK.ChouJ.J.Structural investigation of" exact="rimantadine" post="inhibition of the AM2-BM2 chimera channel of influenza virusesStructure1920111655166310.1016/j.str.2011.09.00322078564"/>
 <result pre="substituent of the 1-aminoethyl pharmacophore group on the potency of" exact="rimantadine" post="against influenza virusA. Bioorg. Med. Chem. Lett.17200769269610.1016/j.bmcl.2006.10.09217113287 ThielG.BaumeisterD.SchroederI.KastS.M.Van EttenJ.L.MoroniA.Minimal"/>
 <result pre="activity of influenza A virus M2 protein: characterization of the" exact="amantadine" post="blockJ. Virol.671993558555947688826 WangJ.CadyS.D.BalannikV.PintoL.H.DeGradoW.F.HongM.Discovery of spiro-piperidine inhibitors and their modulation"/>
 <result pre="channel HHS public accessJ. Am. Chem. Soc.1412019116671167610.1021/jacs.9b0513631264413 WingfieldW.L.PollackD.GrunertR.R.Therapeutic efficacy of" exact="amantadine" post="HCl and rimantadine HCl in naturally occurring influenza A2"/>
 <result pre="accessJ. Am. Chem. Soc.1412019116671167610.1021/jacs.9b0513631264413 WingfieldW.L.PollackD.GrunertR.R.Therapeutic efficacy of amantadine HCl and" exact="rimantadine" post="HCl in naturally occurring influenza A2 respiratory illness in"/>
 <result pre="respiratory illness in manN. Engl. J. Med.281196957958410.1056/NEJM1969091128111024897137 WrightA.K.BatsomboonP.DaiJ.HungI.ZhouH.-X.DudleyG.B.CrossT.A.Differential binding of" exact="rimantadine" post="enantiomers to influenza A M2 proton channelJ. Am. Chem."/>
 <result pre="cytotoxic concentration EC50 50% effective concentration HA hemagglutinin HMA hexamethylene" exact="amiloride" post="IAV influenza A virus IC50 50% inhibitory concentration MDCK"/>
</results>
